Cargando…
Ataluren—Promising Therapeutic Premature Termination Codon Readthrough Frontrunner
Around 12% of hereditary disease-causing mutations are in-frame nonsense mutations. The expression of genes containing nonsense mutations potentially leads to the production of truncated proteins with residual or virtually no function. However, the translation of transcripts containing premature sto...
Autor principal: | Michorowska, Sylwia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8398184/ https://www.ncbi.nlm.nih.gov/pubmed/34451881 http://dx.doi.org/10.3390/ph14080785 |
Ejemplares similares
-
Caffeine boosts Ataluren's readthrough activity
por: Lentini, Laura, et al.
Publicado: (2019) -
Pharmaceuticals Promoting Premature Termination Codon Readthrough: Progress in Development
por: Li, Shan, et al.
Publicado: (2023) -
Advances in therapeutic use of a drug-stimulated translational readthrough of premature termination codons
por: Dabrowski, Maciej, et al.
Publicado: (2018) -
Ataluren suppresses a premature termination codon in an MPS I-H mouse
por: Wang, Dan, et al.
Publicado: (2022) -
The unfolded protein response affects readthrough of premature termination codons
por: Oren, Yifat S, et al.
Publicado: (2014)